Tipranavir has the ability to inhibit the replication of viruses that are resistant to other protease inhibitors and is recommended for patients who are resistant to other treatments. Resistance to tipranavir itself seems to require multiple mutations.[3] Tipranavir was approved by the Food and Drug Administration (FDA) on June 22, 2005, and was approved for pediatric use on June 24, 2008.[4]
Tipranavir should only be taken in combination with ritonavir and other antiretroviral drugs, and is not approved for treatment-naïve patients.[2] Like lopinavir and atazanavir, it is very potent and is effective in salvage therapy for patients with drug resistance. However, side effects of tipranavir may be more severe than those of other antiretrovirals. Some side effects include intracranial hemorrhage, hepatitis, hepatic decompensation, hyperglycemia and diabetes mellitus. The drug has also been shown to cause increases in total cholesterol and triglycerides.[2]
^"FDA-sourced list of all drugs with black box warnings (Use Download Full Results and View Query links.)". nctr-crs.fda.gov. FDA. Retrieved 22 Oct 2023.
^ abcd"Aptivus- tipranavir capsule, liquid filled Aptivus- tipranavir solution". DailyMed. 26 June 2020. Retrieved 2 December 2020.
^Doyon L, Tremblay S, Bourgon L, Wardrop E, Cordingley MG (October 2005). "Selection and characterization of HIV-1 showing reduced susceptibility to the non-peptidic protease inhibitor tipranavir". Antiviral Research. 68 (1): 27–35. doi:10.1016/j.antiviral.2005.07.003. PMID 16122817.
^"New Aptivus (tipranavir) Oral Solution Approved for Treatment-Experienced Pediatric and Adolescent HIV Patients" (Press release). Boehringer Ingelheim. 2008-06-24. Retrieved 2008-09-02.
External linksedit
"Tipranavir". Drug Information Portal. U.S. National Library of Medicine.
tipranavir, tipranavir, disodium, nonpeptidic, protease, inhibitor, manufactured, boehringer, ingelheim, under, trade, name, aptivus, administered, with, ritonavir, combination, therapy, treat, infection, citation, needed, clinical, datapronunciation, ɪər, vee. Tipranavir TPV or tipranavir disodium is a nonpeptidic protease inhibitor PI manufactured by Boehringer Ingelheim under the trade name Aptivus ˈ ae p t ɪ v e s AP tiv es It is administered with ritonavir in combination therapy to treat HIV infection citation needed TipranavirClinical dataPronunciation t ɪ p ˈ r ae n e v ɪer tip RAN e veerTrade namesAptivusAHFS Drugs comMonographMedlinePlusa606009License dataEU EMA by INN US DailyMed Tipranavir US FDA TipranavirPregnancycategoryAU B3Routes ofadministrationBy mouth soft capsules ATC codeJ05AE09 WHO Legal statusLegal statusUK POM Prescription only US WARNING 1 Rx only 2 EU Rx onlyPharmacokinetic dataProtein binding99 9 MetabolismLiverElimination half life4 8 6 hoursExcretionFeces 82 3 urine 4 4 IdentifiersIUPAC name N 3 1R 1 2R 6 hydroxy 4 oxo 2 2 phenylethyl 2 propyl 3 4 dihydro 2H pyran 5 yl propyl phenyl 5 trifluoromethyl pyridine 2 sulfonamideCAS Number174484 41 4 YPubChem CID54682461DrugBankDB00932 YChemSpider10482313 YUNIIZZT404XD09ChEMBLChEMBL183041 NNIAID ChemDB032941PDB ligandTPV PDBe RCSB PDB CompTox Dashboard EPA DTXSID6048622ECHA InfoCard100 158 066Chemical and physical dataFormulaC 31H 33F 3N 2O 5SMolar mass602 67 g mol 13D model JSmol Interactive imageSMILES CCC C 1 CC O C C O O1 C H CC c3cccc NS O O c2ccc cn2 C F F F c3 CCc4ccccc4InChI InChI 1S C31H33F3N2O5S c1 3 16 30 17 15 21 9 6 5 7 10 21 19 26 37 28 29 38 41 30 25 4 2 22 11 8 12 24 18 22 36 42 39 40 27 14 13 23 20 35 27 31 32 33 34 h5 14 18 20 25 36 37H 3 4 15 17 19H2 1 2H3 t25 30 m1 s1 YKey SUJUHGSWHZTSEU FYBSXPHGSA N Y N Y what is this verify Tipranavir has the ability to inhibit the replication of viruses that are resistant to other protease inhibitors and is recommended for patients who are resistant to other treatments Resistance to tipranavir itself seems to require multiple mutations 3 Tipranavir was approved by the Food and Drug Administration FDA on June 22 2005 and was approved for pediatric use on June 24 2008 4 Tipranavir should only be taken in combination with ritonavir and other antiretroviral drugs and is not approved for treatment naive patients 2 Like lopinavir and atazanavir it is very potent and is effective in salvage therapy for patients with drug resistance However side effects of tipranavir may be more severe than those of other antiretrovirals Some side effects include intracranial hemorrhage hepatitis hepatic decompensation hyperglycemia and diabetes mellitus The drug has also been shown to cause increases in total cholesterol and triglycerides 2 Aptivus labeling has a black box warning regarding hepatotoxicity and intracranial hemorrhage 2 References edit FDA sourced list of all drugs with black box warnings Use Download Full Results and View Query links nctr crs fda gov FDA Retrieved 22 Oct 2023 a b c d Aptivus tipranavir capsule liquid filled Aptivus tipranavir solution DailyMed 26 June 2020 Retrieved 2 December 2020 Doyon L Tremblay S Bourgon L Wardrop E Cordingley MG October 2005 Selection and characterization of HIV 1 showing reduced susceptibility to the non peptidic protease inhibitor tipranavir Antiviral Research 68 1 27 35 doi 10 1016 j antiviral 2005 07 003 PMID 16122817 New Aptivus tipranavir Oral Solution Approved for Treatment Experienced Pediatric and Adolescent HIV Patients Press release Boehringer Ingelheim 2008 06 24 Retrieved 2008 09 02 External links edit Tipranavir Drug Information Portal U S National Library of Medicine Portals nbsp Medicine nbsp Viruses Retrieved from https en wikipedia org w index php title Tipranavir amp oldid 1187672353, wikipedia, wiki, book, books, library,
